ATE150320T1 - Zusammensetzung mit verzögerter wirkstoffabgabe enthaltend ein multivalentes kation verzetztes alginat kombiniert mit einem polyacrylsäure - Google Patents

Zusammensetzung mit verzögerter wirkstoffabgabe enthaltend ein multivalentes kation verzetztes alginat kombiniert mit einem polyacrylsäure

Info

Publication number
ATE150320T1
ATE150320T1 AT94307259T AT94307259T ATE150320T1 AT E150320 T1 ATE150320 T1 AT E150320T1 AT 94307259 T AT94307259 T AT 94307259T AT 94307259 T AT94307259 T AT 94307259T AT E150320 T1 ATE150320 T1 AT E150320T1
Authority
AT
Austria
Prior art keywords
alginate
agents
polyacrylic acid
interaction
consolidated
Prior art date
Application number
AT94307259T
Other languages
English (en)
Inventor
W R Gombotz
R J Mumper
L S Bouchard
A S Hoffman
Original Assignee
Bristol Myers Squibb Co
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Univ Washington filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE150320T1 publication Critical patent/ATE150320T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
AT94307259T 1993-10-15 1994-10-04 Zusammensetzung mit verzögerter wirkstoffabgabe enthaltend ein multivalentes kation verzetztes alginat kombiniert mit einem polyacrylsäure ATE150320T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/138,367 US5451411A (en) 1993-10-15 1993-10-15 Methods and compositions for the oral delivery of therapeutic agents

Publications (1)

Publication Number Publication Date
ATE150320T1 true ATE150320T1 (de) 1997-04-15

Family

ID=22481704

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94307259T ATE150320T1 (de) 1993-10-15 1994-10-04 Zusammensetzung mit verzögerter wirkstoffabgabe enthaltend ein multivalentes kation verzetztes alginat kombiniert mit einem polyacrylsäure

Country Status (9)

Country Link
US (1) US5451411A (de)
EP (1) EP0652015B1 (de)
JP (1) JPH07258115A (de)
AT (1) ATE150320T1 (de)
CA (1) CA2133271A1 (de)
DE (1) DE69402153T2 (de)
DK (1) DK0652015T3 (de)
ES (1) ES2100632T3 (de)
GR (1) GR3023307T3 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619660D0 (en) * 1996-09-20 1996-11-06 Scient Hospital Suppl Int Ltd Prevention of gastrointestinal damage
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
EP2138191A1 (de) 1998-01-05 2009-12-30 University Of Washington Erhöhter Transport unter Benutzung membranzerstörender Stoffe
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
EP1374908A3 (de) * 1998-10-09 2004-03-24 The Regents Of The University Of Michigan Polymere-Arzneimittel Konjugate die eine Hydrazidolinkergruppe enthalten
JP2002539172A (ja) 1999-03-17 2002-11-19 ノバルティス アクチエンゲゼルシャフト Ｔｇｆ−ベータを含む医薬組成物
AU6232899A (en) * 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
WO2001051092A2 (en) 2000-01-07 2001-07-19 University Of Washington Enhanced transport of agents using membrane disruptive agents
US6596310B1 (en) 2000-08-23 2003-07-22 Board Of Trustees Operating Michigan State University Method of artificial insemination by timed release of sperm from capsules or solid beads
US6676958B2 (en) * 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
US20030206957A1 (en) * 2002-05-06 2003-11-06 Scherr George H. Orally administered medicament delivery systems
CA2515213A1 (en) * 2003-02-11 2004-08-26 University Of Washington Stimuli-responsive polymer conjugates and related methods
JP4822092B2 (ja) * 2003-09-01 2011-11-24 大正製薬株式会社 Ｗ／ｏ／ｗ型複合エマルション
DE10350248A1 (de) * 2003-10-28 2005-06-16 Magnamedics Gmbh Thermosensitive, biokompatible Polymerträger mit veränderbarer physikalischer Struktur für die Therapie, Diagnostik und Analytik
US7744895B2 (en) 2005-08-31 2010-06-29 Yamanashi University Methods of treating allergies using TGF-β1 and allergens
WO2007109584A1 (en) * 2006-03-16 2007-09-27 University Of Washington Temperature-and ph-responsive polymer compositions
KR101396776B1 (ko) 2006-07-04 2014-05-22 스펌바이탈 에이에스 정자의 보존 및 조절된 전달/방출
US7981688B2 (en) 2007-03-08 2011-07-19 University Of Washington Stimuli-responsive magnetic nanoparticles and related methods
US20080292663A1 (en) * 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
DE102007059939A1 (de) 2007-12-12 2009-06-18 Müller-Schulte, Detlef, Dr. Auflösbare, magnetische und unmagnetische Polymerträger zur Abtrennung und Wiedergewinnung von Zellen und Biosubstanzen
IT1392471B1 (it) * 2008-11-25 2012-03-09 Pharmafilm S R L Collutorio in forma di sospensione stabile comprendente microsfere che incorporano un principio attivo.
US8426214B2 (en) * 2009-06-12 2013-04-23 University Of Washington System and method for magnetically concentrating and detecting biomarkers
US9080933B2 (en) 2009-11-09 2015-07-14 University Of Washington Through Its Center For Commercialization Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates
US20110117668A1 (en) * 2009-11-09 2011-05-19 University Of Washington Through Its Center For Commercialization Self-powered smart diagnostic devices
US20130156858A1 (en) * 2010-06-03 2013-06-20 Rph Pharmaceuticals Ab Formulations Preserving Bioactivity and Methods of Their Preparation
US9165703B2 (en) * 2010-08-25 2015-10-20 Brown University Methods and systems for prolonged localization of drug delivery
US20120213856A1 (en) * 2011-02-23 2012-08-23 Po-Lun Wang Manufacturing Method of Microcapsule
AU2013204906B2 (en) 2012-03-12 2016-01-07 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
US11596607B2 (en) * 2017-04-18 2023-03-07 Actorious Innovations And Research Pvt. Ltd. Polymer based formulation for release of drugs and bioactives at specific GIT sites

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8323624D0 (en) * 1983-09-02 1983-10-05 Reckitt & Colmann Prod Ltd Medicinal compositions
EP0159604B1 (de) * 1984-04-09 1990-11-07 Toyo Boseki Kabushiki Kaisha Präparat mit verzögerter Freigabe zum Aufbringen auf die Schleimhäute der Mundhöhle
CA1215922A (en) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4933185A (en) * 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
CA1321048C (en) * 1987-03-05 1993-08-10 Robert W. J. Lencki Microspheres and method of producing same
US4923645A (en) * 1987-11-16 1990-05-08 Damon Biotech, Inc. Sustained release of encapsulated molecules
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent

Also Published As

Publication number Publication date
EP0652015A2 (de) 1995-05-10
DE69402153T2 (de) 1997-10-09
GR3023307T3 (en) 1997-08-29
US5451411A (en) 1995-09-19
ES2100632T3 (es) 1997-06-16
EP0652015B1 (de) 1997-03-19
JPH07258115A (ja) 1995-10-09
DK0652015T3 (da) 1997-04-14
DE69402153D1 (de) 1997-04-24
CA2133271A1 (en) 1995-04-16
EP0652015A3 (de) 1995-08-02

Similar Documents

Publication Publication Date Title
DE69402153D1 (de) Zusammensetzung mit verzögerter Wirkstoffabgabe enthaltend ein multivalentes Kation verzetztes Alginat kombiniert mit einem Polyacrylsäure
DK0725648T3 (da) Leverspecifikke farmaceutiske aktivstoffer
WO1996025947A3 (en) Induction of e-selectin for targetting therapeutic agents
NO306655B1 (no) Anvendelse av GLA, DGLA eller LA ved fremstilling av et medisinsk preparat
WO1991014437A3 (en) Use of copper(ii) containing compounds to accelerate wound healing
HU902145D0 (en) Process for producing medical preparatives suitable for systematic treating of preneoplastic lesions with cytoquinine content
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
DK0721501T3 (da) Farmaceutisk præparat der omfatter phosphatase eller et derivat deraf
FI962154A7 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
DE69836352D1 (de) Transdermales therapeutisches Pflaster mit Capsaicin und seinen Analogen
IL106725A (en) Pharmaceutical composition for treating inflammatory bowel disease comprising IL-10
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
HUT67479A (en) Process for producing cellulose-containing cereal extracts
IT9021766A0 (it) Composizioni terapeutiche transdermali contenenti farmaco e/o agente promotore dell'assorbimento cutaneo supportato su particelle microporose e microsfere polimeriche e loro preparazione
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
BR9406720A (pt) Utilização de um adenovírus recombinante de origem animal adenovírus recombinante de origem animal e composição farmacêutica compreendendo um ou vários adenovírus
EP0734723A4 (de) Therapeutisches präparat zur behandlung von hyperparathyroidismus bei dialysepatienten
DE69831928D1 (de) Von Willenbrand Faktor (vWF) enthaltende Zubereitung, verfahren zür Herstellung von vWF enthaltenden Zubereitungen und deren Verwendung
BR9500436A (pt) Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
CA2202397A1 (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
DE59002748D1 (de) Verfahren zur Herstellung von Mitteln zur Therapie von Hauterkrankungen.
DE68924006D1 (de) Pharmazeutische Zusammensetzungen mit Eierschalenbestandteilen und ihre Herstellung und Verwendung.
IL107153A (en) Pharmaceutical compositions for preventing insulin-dependent diabetes mellitus comprising IL10 and method for their manufacture
ATE200617T1 (de) Pharmazeutische zusammensetzungen zur transdermalen verabreichung von melatonin und/oder seine analoge

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee